BTAI Articles, BioXcel Therapeutics Inc. - From 02/09/24

U.S. stocks traded mixed this morning, with the S&P 500 topping the 5,000 mark on Friday. Following the market opening Friday, the Dow traded d...

Shares of Cloudflare, Inc. (NYSE: NET) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-qua...

NEW HAVEN, Conn., Feb. 08, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the "Company") (NASDAQ:BTAI), a biopharmaceutical company utiliz...

Aligns with Company's strategic focus on bringing to market BXCL501 for potential acute treatment of agitation for Alzheimer's patients...

Vincent J. O'Neill, M.D., promoted to Executive Vice President, Chief of Product Development and Medical Officer   Rajiv Patni, M.D., appoi...

Company to review BXCL502 and other potential emerging pipeline candidates   Dr. Jeffrey Cummings to discuss agitation relief in Alzheimer'...

Shares of Beyond Air, Inc. (NASDAQ: XAIR) dipped during Tuesday’s session following weak quarterly results. Beyond Air posted a quarterly lo...

BioXcel Therapeutics Inc (NASDAQ: BTAI) announced alignment with the FDA's recommendation for a Phase 3 trial in the TRANQUILITY program o...

BioXcel Therapeutics Inc (NASDAQ: BTAI) announced overall survival (OS) data from its Phase 2 trial of BXCL701 in combination with Merck ...

NEW HAVEN, Conn., Oct. 31, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial i...